Constellation Brands Free cash flow decreased by 7.3% to $343.90M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 10.2%, from $312.10M to $343.90M. Over 4 years (FY 2022 to FY 2026), Free cash flow shows relatively stable performance with a -0.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $602.10M | $570.40M | $672.90M | $0.00 | $561.60M | $657.70M | $377.50M | $124.70M | $388.40M | $651.60M | $394.90M | $76.00M | $315.20M | $854.00M | $456.80M | $312.10M | $444.40M | $634.80M | $370.90M | $343.90M |
| QoQ Change | — | -5.3% | +18.0% | -100.0% | — | +17.1% | -42.6% | -67.0% | +211.5% | +67.8% | -39.4% | -80.8% | +314.7% | +170.9% | -46.5% | -31.7% | +42.4% | +42.8% | -41.6% | -7.3% |
| YoY Change | — | — | — | — | -6.7% | +15.3% | -43.9% | — | -30.8% | -0.9% | +4.6% | -39.1% | -18.8% | +31.1% | +15.7% | +310.7% | +41.0% | -25.7% | -18.8% | +10.2% |